First Trust Mid Cap Growth AlphaDEX Fund
FNY - ETF AI Analysis
Top Page
First Trust Mid Cap Growth AlphaDEX Fund (FNY)
FNY, the First Trust Mid Cap Growth AlphaDEX Fund, earns its overall rating largely thanks to strong contributors like Exelixis and Coca-Cola Bottling Co Consolidated, which show solid financial performance, profitability, and positive momentum. At the same time, holdings such as Glaukos and Lifestance Health Group face profitability and valuation challenges that modestly weigh on the fund’s appeal. A key risk factor is that several top holdings show overbought technical signals and leverage or valuation concerns, which could increase volatility for investors.
FNY vs. SPDR S&P 500 ETF (SPY)
- AUM
- 529.07M
- Region
- North America
- Expense Ratio
- 0.73%
- Beta
- 1.07
- Issuer
- First Trust
- Inception Date
- Apr 19, 2011
- Dividend Yield
- 0.50%
- Asset Class
- Equity
- Index Tracked
- NASDAQ AlphaDEX Mid Cap Growth Index
FNY Summary
FNY is an exchange-traded fund that follows the NASDAQ AlphaDEX Mid Cap Growth Index, focusing on medium-sized U.S. companies with room to grow. It spreads your money across many sectors, with a tilt toward health care and technology. Some of its holdings include GitLab and Charles River Labs, which are involved in software and medical research services. Investors might consider FNY if they want growth potential and diversification beyond the biggest, well-known large companies. A key risk is that mid-sized growth stocks can be more volatile, so the fund’s value can go up and down sharply with the market.
How much will it cost me?
This ETF has an expense ratio of 0.73%, which means you’ll pay about $7.30 per year for every $1,000 invested. That’s higher than the average ETF because it uses an active, rules-based AlphaDEX strategy rather than simple passive index tracking.
What would affect this ETF?
FNY could benefit if the U.S. economy continues to grow, supporting mid-sized health care and technology companies like Gitlab and Dynatrace, and if innovation and digital payment trends help its top holdings such as Remitly. On the downside, higher interest rates, slower economic growth, or tighter health care and financial regulations could hurt mid-cap growth stocks and make this U.S.-focused, growth-oriented ETF more volatile.
FNY Top 10 Holdings
FNY is leaning hard into mid-cap growth, with a clear tilt toward U.S. health care and tech names that have been powering ahead lately. Cybersecurity player Qualys and data-protection firm Rubrik are rising, helping to pull the fund higher, while GitLab’s strong growth story adds more tech fuel despite some profitability wrinkles. On the health care side, Hinge Health and Concentra are showing strong momentum, though their still-evolving business models can make the ride bumpy. Overall, performance is being driven by a cluster of innovative, U.S.-based growth companies.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 GKOS | Glaukos | 1.04% | $5.59M | $13.28B | 174.37% | 61Neutral |
 CON | Concentra Group Holdings Parent, Inc. | 0.94% | $5.02M | $5.34B | 125.65% | 66Neutral |
 VSXY | Victoria's Secret | 0.93% | $4.99M | $8.62B | 197.49% | 71Outperform |
 PACS | PACS Group Inc | 0.91% | $4.88M | $7.87B | 297.44% | 66Neutral |
 EXEL | Exelixis | 0.91% | $4.87M | $16.98B | 70.51% | 78Outperform |
 HNGE | Hinge Health, Inc. Class A | 0.91% | $4.87M | $9.34B | 162.85% | 70Outperform |
 CHYM | Chime Financial, Inc. Class A | 0.90% | $4.81M | $11.83B | 73.19% | 64Neutral |
 LFST | Lifestance Health Group | 0.87% | $4.68M | $5.24B | 120.32% | 61Neutral |
 CRL | Charles River Labs | 0.87% | $4.68M | $16.17B | 97.52% | 60Neutral |
 HAE | Haemonetics | 0.87% | $4.66M | $5.46B | 78.71% | 70Outperform |
FNY Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FNY, the sentiment is Negative. The current price of 95.55 is below the 20-day moving average (MA) of 97.83, below the 50-day MA of 99.36, and below the 200-day MA of 100.16, indicating a bearish trend. The MACD of -0.76 indicates Positive momentum. The RSI at 41.88 is Neutral, neither overbought nor oversold. The STOCH value of 30.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FNY.
FNY Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| FNY | $95.55 | $102.00(6.75% Upside) | $529.07M | 0.73% | 67Neutral |
 RFG | $54.53 | $72.54(33.02% Upside) | $297.88M | 0.35% | 73Outperform |
 NUMG | $42.86 | $54.66(27.54% Upside) | $295.44M | 0.31% | 69Neutral |
 GLRY | $36.05 | $44.85(24.41% Upside) | $150.11M | 0.80% | 74Outperform |
 FRTY | $20.18 | $25.79(27.80% Upside) | $128.40M | 0.60% | 61Neutral |
 TMFM | $22.20 | $26.92(21.26% Upside) | $110.34M | 0.85% | 67Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FNY | First Trust Mid Cap Growth AlphaDEX Fund | 95.55 | 4.24 | 4.65% | |
| RFG | Invesco S&P Midcap 400 Pure Growth ETF | 54.53 | 2.50 | 4.81% | |
| NUMG | Nuveen ESG Mid-Cap Growth ETF | 42.86 | -5.30 | -11.01% | |
| GLRY | Inspire Faithward Mid Cap Momentum ESG ETF | 36.05 | -0.23 | -0.63% | |
| FRTY | Alger Mid Cap 40 ETF | 20.18 | -1.26 | -5.86% | |
| TMFM | Motley Fool Mid-Cap Growth ETF | 22.20 | -1.54 | -6.49% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.